BioSpace News Archive

After almost 10 years of service as the CEO of Tegra Medical and as Head of the Medical division within the SFS Group, J. Mark King has decided to retire as of August 1, 2020 . The Board of Directors and the Group Executive Board thank J. Mark King for his many years of service, his contribution to the development of Tegra Medical

Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and diseases associated with the microbiome, announced the appointment of William Delaney, PhD as Chief Scientific Officer, Virology, replacing Richard Colonno, PhD, who will retire and transition from this role on June 1, 2020.

IntelGenx Corp. announced that the U.S. Food & Drug Administration has granted the Company’s request for a Type A meeting related to its RIZAPORT® VersaFilm® program.

Onxeo S.A., a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response, in particular against rare or resistant cancers, announced the publication of an initiation report by Bryan Garnier & Co, a leading independent European financial services company specialized in research, execution and advisory services.

MEI Pharma, Inc., a late-stage pharmaceutical company focused on advancing new therapies for cancer, announced that Daniel P. Gold, Ph.D., president and chief executive officer of MEI, will present a company overview and business update at the Jefferies Virtual Healthcare Conference on Tuesday, June 2nd, 2020 at 11:00 AM Eastern Time.

Synlogic will host its first Virtual R&D Event which will include presentations from members of the Synlogic executive team providing an in-depth review of Synlogic’s Synthetic Biotic platform and programs for the treatment of metabolic diseases, inflammatory and immune disorders, and cancer.

Novel Cocrystal Form of AV-101 Administered with Probenecid May Have Superior Delivery, an Enhanced Therapeutic Profile and Additional Intellectual Property Protection [27-May-2020] SOUTH SAN FRANCISCO, Calif. , May 27, 2020 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for anxiet

IVERIC bio, Inc. announced that Pravin Dugel, MD, Executive Vice President and Chief Strategy and Business Officer will present an overview of the Company at the Jefferies 2020 Virtual Healthcare Conference, on Wednesday, June 3 at 9:00 a.m. Eastern Time.

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that Chief Executive Officer David L. Lucchino will present a company overview at the Jefferies Virtual Healthcare Conference and participate in a “fireside chat” at the Goldman Sachs Annual Global Hea

Company further expands executive leadership with the appointment of Mark Meltz as Chief Operating Officer and General Counsel